PMID- 33026571
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20211006
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 53
IP  - 6
DP  - 2021 Jun
TI  - Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor 
      (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a 
      systematic review and meta-analysis.
PG  - 1139-1147
LID - 10.1007/s11255-020-02671-z [doi]
AB  - PURPOSE: HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor) was 
      developed to improve renal anemia. This study was to evaluate the efficiency and 
      safety of HIF-PHI in patients with non-dialysis-dependent chronic kidney disease 
      (NDD-CKD). METHODS: The literature was extracted from PubMed, EMBASE, the 
      Cochrane Central Register of Controlled Trials, and the Wanfang database. 
      Statistical tests and forest plots were depicted by Review Manager Version 5.3. 
      The primary outcome was a change in hemoglobin level from baseline (DeltaHb). 
      Secondary outcomes were changes in ferritin (DeltaFerritin), hepcidin (DeltaHepcidin), 
      and transferrin saturation from baseline (DeltaTSAT), and adverse events (AEs). This 
      study is registered with PROSPERO (registration number CRD42020199656). RESULTS: 
      Ten trials were included. The results showed that HIF-PHI improved the DeltaHb [SMD 
      3.03 (95% CI 2.10, 3.96), P < 0.00001] in NDD patients. HIF-PHI reduced hepcidin 
      levels in the NDD patients [SMD - 1.44 (95% CI - 2.19-0.70), P = 0.0002]. 
      DeltaFerritin values were reduced significantly in the HIF-PHI group [SMD - 1.08 (95% 
      CI - 1.63-0.53), P = 0.0001]. However, DeltaTSAT values showed no significant 
      difference in the HIF-PHI group compared to the placebo group [SMD - 0.23 (95% CI 
      - 0.66-0.21), P = 0.31]. In the safety assessment, HIF-PHI did not increase 
      adverse events significantly [RR 0.98 (95% CI 0.88-1.10), P = 0.74]. CONCLUSION: 
      HIF-PHI improves renal anemia and iron utilization disorder in NDD-CKD patients, 
      without significantly more adverse events.
FAU - Zhang, Siliang
AU  - Zhang S
AD  - Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical 
      University, Lingjiang Road, Yuzhong District, Chongqing, 400010, China.
FAU - Guo, Jing
AU  - Guo J
AD  - Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 
      400030, China.
FAU - Xie, Shuqin
AU  - Xie S
AD  - Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical 
      University, Lingjiang Road, Yuzhong District, Chongqing, 400010, China.
FAU - Chen, Jianwei
AU  - Chen J
AD  - Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical 
      University, Lingjiang Road, Yuzhong District, Chongqing, 400010, China.
FAU - Yu, Shenrun
AU  - Yu S
AD  - Center of Urology and Nephrology, Yongchuan People's Hospital of Chongqing, 
      Chongqing, 402160, China.
FAU - Yu, Yuan
AU  - Yu Y
AD  - Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical 
      University, Lingjiang Road, Yuzhong District, Chongqing, 400010, China. 
      yuyuan@cqmu.edu.cn.
LA  - eng
GR  - Ycstc, 2019nb0215/Natural Science Foundation of Yongchuan District/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201007
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - EC 1.14.11.29 (Hypoxia-Inducible Factor-Proline Dioxygenases)
SB  - IM
MH  - Anemia/*drug therapy/etiology
MH  - Humans
MH  - Hypoxia-Inducible Factor-Proline Dioxygenases/*antagonists & inhibitors
MH  - Renal Dialysis
MH  - Renal Insufficiency, Chronic/complications
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Hypoxia-inducible factor prolyl hydroxylase inhibitor
OT  - Meta-analysis
OT  - Renal anemia
EDAT- 2020/10/08 06:00
MHDA- 2021/10/07 06:00
CRDT- 2020/10/07 12:11
PHST- 2020/05/25 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
PHST- 2020/10/07 12:11 [entrez]
AID - 10.1007/s11255-020-02671-z [pii]
AID - 10.1007/s11255-020-02671-z [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2021 Jun;53(6):1139-1147. doi: 10.1007/s11255-020-02671-z. Epub 
      2020 Oct 7.